Information  X 
Enter a valid email address

C4X Discovery (C4XD)


Friday 26 November, 2021

C4X Discovery

Clive Dix wins OBN Special Recognition Award

RNS Number : 7418T
C4X Discovery Holdings PLC
26 November 2021

C4X Discovery Holdings plc


("C4XD", "C4X Discovery" or the "Company")


C4X Discovery CEO, Clive Dix, receives OBN Special Recognition Award 2021



26 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), is honoured to announce that CEO, Dr Clive Dix has received the Special Recognition Award at the OBN 2021 Awards for his life-long contribution to the UK life sciences industry. 


Eva-Lotta Allan, Chairman of C4X Discovery, commented: "The prestigious OBN Awards celebrate the very best of UK life science.  We are therefore very proud of all that Clive has achieved throughout his career, and in particular, here at C4XD.  Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive.  He has the scientific expertise, industry experience and leadership qualities that are needed to grow companies in such a challenging industry.  Over the past year, in addition to his corporate work, Clive has played a leading role in the UK Vaccine Taskforce which has been recognised as leading one of the most successful rollouts of the COVID-19 vaccination globally.  Clive is an inspiration to us here at C4XD and it is wonderful to see the recognition across the industry for all his contributions to our thriving life sciences sector."


- Ends -




C4X Discovery Holdings

Mo Noonan, Communications

+44 (0)787 6444977

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)

C4X Discovery Media - Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700


Notes to Editors:


About C4X Discovery


C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.


We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at or follow us on twitter @C4XDiscovery .



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t